Trial Profile

A clinical study to evaluate the biological effects of pre-operative intravenous administration of JX-594 (thymidine kinase-deactivated Vaccinia virus plus GM-CSF) prior to planned surgical resection of locally advanced/poor prognosis or metastatic cancers

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pexastimogene devacirepvec (Primary)
Indications Bladder cancer; Colorectal cancer; Liver cancer; Malignant melanoma; Renal cell carcinoma
Focus Pharmacokinetics
Acronyms Pre-Operative-JX594

03 Apr 2019 Status changed from active, no longer recruiting to completed.
19 Sep 2018 According to a Transgene media release, the final data from this trial will be published in an upcoming paper and will be presented at a future scientific conference.
05 Jun 2018 Results (n=8) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com